Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,185.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the sale, the director now directly owns 69,938 shares in the company, valued at approximately $484,670.34. This represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The shares were sold at an average price of $6.98, for a total value of $31,410.00.

Health Catalyst Trading Up 3.8 %

Shares of NASDAQ:HCAT opened at $7.34 on Friday. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The business has a 50 day moving average of $7.87 and a 200-day moving average of $7.48. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market cap of $446.64 million, a PE ratio of -5.44 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) earnings per share. As a group, equities research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

HCAT has been the subject of several recent analyst reports. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Stephens increased their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Citigroup boosted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its holdings in Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares during the period. Rhumbline Advisers grew its position in Health Catalyst by 9.1% during the second quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after buying an additional 7,589 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Health Catalyst by 276.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after acquiring an additional 156,908 shares during the period. Acadian Asset Management LLC raised its holdings in Health Catalyst by 1.3% in the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock valued at $4,690,000 after acquiring an additional 9,697 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its position in shares of Health Catalyst by 1.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares during the period. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.